Sanofi SA has stepped up its investment in messenger RNA (mRNA) with plans to create a new unit devoted exclusively to the technology in Cambridge, Mass, US, and Marcy l’Etoile, Lyon, France. On 29 June, the company announced plans to spend €400 million per year to accelerate the research and development of mRNA vaccines against a broad group of infectious diseases.
